U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07429266) titled 'A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)' on Feb. 18.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, & Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Polycythemia Vera
Intervention:
DRUG: Sapablursen
Administered subcutaneo...